IGC Pharma
29 hedge funds and large institutions have $7.9M invested in IGC Pharma in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 7 closing their positions.
110% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $568K
0.14% more ownership
Funds ownership: 9.81% → 9.95% (+0.14%)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1% less capital invested
Capital invested by funds: $7.97M → $7.9M (-$70K)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$455K |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$426K |
| 3 |
State Street
Boston,
Massachusetts
|
+$331K |
| 4 |
VF
Virtu Financial
New York
|
+$290K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
-$572K |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
-$212K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$127K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$116K |
| 5 |
BlackRock
New York
|
-$103K |
IGC Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2021, worth a combined $7.9M — down 0.88% from $7.97M a quarter earlier.
Fund positioning in IGC was balanced in Q2 2021: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $455K. The largest seller was Carroll Financial Associates, exiting entirely with an estimated $572K sold.
- 29 institutional investors held IGC Pharma (IGC) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $7.9M of IGC Pharma stock for Q2 2021, down 0.88% quarter-over-quarter.
- 7 funds opened new IGC Pharma positions in Q2 2021 and 7 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q2 2021 was Renaissance Technologies, an estimated $455K added.
- The largest IGC Pharma seller in Q2 2021 was Carroll Financial Associates, an estimated $572K sold.
Based on aggregated 13F filings for Q2 2021.